Managed Access Programs for VAY736, Ianalumab

Conditions

• Primary Immune Thrombocytopenia
• Sjögren's Syndrome

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• ianalumab — DRUG
  Patients receive ianalumab

Study Details

The purpose of this registration is to list Managed Access Programs (MAPs) related to VAY736, ianalumab

Key Dates

Status verified

Feb 2026

Central Contacts

• MAP requests are initiated by a licensed physician. https// www.novart is.com/healthcare-professionals/managed-access-programs
  1-888-669-6682
  [email protected]
• Novartis Pharmaceuticals
  +41613241111
  [email protected]

Related Studies

• Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
  PHASE2 · Recruiting · Pfizer · Greenville, North Carolina
• A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
  PHASE3 · Recruiting · Amgen · Avondale, Arizona